Colombia-Based Blueberries Medical Corp Set to Soar
Blueberries Medical Corp (OTCMKTS:BBRRF, CNSX:BBM) is one of the newest cannabis players on the block, having just commenced trading on February 6, 2019.
Blueberries Medical is, without question, one of the best untapped pot stocks out there right now. But it’s not for the risk-averse. It’s a true penny stock, but chances are good that it won’t be a penny stock for long.
Blueberries Medical Corp Overview
Blueberries Medical is looking to become a large-scale producer of naturally grown premium-quality cannabis. It has pre-registered and owns 134 exclusive Colombian cannabis strains with high contents of cannabidiol (CBD) and tetrahydrocannabinol (THC). (Source: “Blueberries Medical Presentation, February 2019,” Blueberries Medical Corp, last accessed March 20, 2019.)
The company is fully licensed for the production, distribution, and international export of CBD- and THC-based medical cannabis in Colombia.
By 2020, the company expects to finish its 1.5-million-square-foot cannabis greenhouse facility capable of producing 84,000 kilograms (around 185,188 pounds) of dried flowers annually.
The company’s headquarters are in Toronto, but its primary growing facilities are actually located in the Bogotá savanna in central Colombia.
Why Colombia? The country has emerged as an industry hotspot and could capture as much as 20% of the global market. Unlike seasonal Canada, Colombia has the perfect climate, legal framework, and production capability.
Climate: Home to natural and consistent 12-hour light cycles and a temperate climate, Colombia has a year-round growing season, which allows Blueberries Medical Corp to maximize on cycles and production yields.
Legal Framework: Colombia legalized medicinal cannabis in December 2015 and is the only equatorial country that allows for the production of cannabis. Three licenses are required: cultivation, extraction, and export.
Production: Colombia has an experienced and available workforce, as well as ultra-low production costs. Furthermore, it obtained a production quota for 44% of global medicinal pot production.
Blueberries Medical Corp is led by an experienced team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology, and marketing.
As mentioned earlier, the company has received all three licenses for the cultivation, production, domestic distribution, and international export of CBD- and THC-based medical cannabis.
Furthermore, Blueberries Medical Corp has partnerships with key players in Europe to distribute and sell the company’s cannabis products.
While some may bristle at the thought of investing in a cannabis player in Colombia, the company is located in one of the country’s safest areas, the Bogotá savanna.
This area in central Colombia is the major production center of cut flowers, accounting for 70% of the nation’s flower production. It is also just 40 miles from the El Dorado International Airport.
In February, Blueberries Medical Corp completed the acquisition of a 37-acre agricultural property in the Bogotá savanna, called the “Zipaquira Property,” for $1.5 million.
The company has the opportunity to acquire or lease additional adjoining land for future projects and capacity expansion. (Source: “Blueberries Medical Acquires an Additional 37 Acres of Prime Agricultural Land to Significantly Increase Cannabis Production Capacity,” Globe Newswire, February 20, 2019.)
In addition to scalability, the land has a limitless supply of water and natural sunlight, which Blueberries Medical Corp expects will significantly reduce its electricity expenses.
The 1.3-million-square-foot cannabis greenhouse will be built in three phases.
The first fully funded phase of approximately 500,000 square feet is expected to yield roughly 66,140 pounds of dried cannabis annually. The company expects that the first phase will be completed and operational in the fourth quarter of 2019.
The property is roughly 15 miles from the company’s existing 107,000-square-foot, fully operational cannabis greenhouse facility on its 7.4-acre Guatavita property.
- 2018: 107,000-square-foot greenhouses with annual production capacity of 6,000 kilograms (about 13,228 pounds).
- 2019: 642,000-square-foot greenhouses with annual production capacity of 36,000 kilograms (about 79,366 pounds).
- 2020: 1.5-million-square-foot greenhouses with annual production capacity of 84,000 kilograms (about 185,188 pounds).
(Source: Blueberries Medical Corp, op cit.)
Essentially, Blueberries has everything needed to help it become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts.
|Blueberries Medical Stock Information|
|Market Cap||$44.8 million|
|Current Share Price||$0.42|
(Source: “Blueberries Medical Corp. (BBRRF),” Yahoo! Finance, last accessed March 20, 2019.)
There isn’t much to go on yet with Blueberries Medical. After all, it only went public in early February. But the company is taking a tack we haven’t really seen much yet in the legal cannabis industry: building greenhouses in South America.
Well, ICC Labs Inc. was acquired by Aurora Cannabis Inc (NYSE:ACB) and Spectrum Cannabis Colombia S.A.S. was acquired by Canopy Growth Corp (NYSE:CGC). And there are a few other publicly traded cannabis stocks with operations in Colombia, but they’re trading significantly higher.
That said, Blueberries Medical Corp has developed the framework to be a leader in the medical cannabis field. It may not be for risk-averse investors, but for those looking for a growth opportunity in the cannabis industry, BBRRF stock is certainly worth researching.